Welcome to our dedicated page for CNS Pharmaceuticals SEC filings (Ticker: CNSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to track Berubicin trial milestones or sudden stock offerings buried in dense biotech disclosures? CNS Pharmaceuticals SEC filings are packed with scientific jargon, frequent capital raises, and rapid-fire updates that overwhelm even seasoned analysts. If you have ever typed “CNS Pharmaceuticals SEC filings explained simply” into a search bar, you already know the challenge.
Stock Titan solves it. Our AI reads every CNS Pharmaceuticals annual report 10-K simplified, dissects each CNS Pharmaceuticals quarterly earnings report 10-Q filing, and flags CNS Pharmaceuticals insider trading Form 4 transactions within minutes of hitting EDGAR. The platform delivers:
- CNS Pharmaceuticals Form 4 insider transactions real-time alerts that spotlight executive buys, sells, and option exercises.
- Interactive breakdowns of R&D spend, cash runway, and dilution risk inside every 10-Q—your shortcut to CNS Pharmaceuticals earnings report filing analysis.
- Plain-English summaries that make “understanding CNS Pharmaceuticals SEC documents with AI” as simple as reading a headline.
- One-click access to CNS Pharmaceuticals proxy statement executive compensation details and board voting matters.
- Event-driven briefs with CNS Pharmaceuticals 8-K material events explained so you never miss a trial update, capital raise, or licensing deal.
Why does this matter? Form 4 data shows whether insiders believe Berubicin’s pivotal study will succeed; 8-Ks reveal FDA feedback; 10-Ks outline the competitive landscape for GBM therapies. With AI-powered summaries, real-time filing updates, and expert context, you can follow CNS Pharmaceuticals executive stock transactions Form 4, compare quarter-over-quarter burn rates, and gauge regulatory momentum—without thumbing through hundreds of pages.
Spend less time parsing disclosures and more time making decisions. Everything you need to monitor CNS Pharmaceuticals’ journey from clinical stage to commercial breakthrough lives here, updated the moment the SEC publishes.
CNS Pharmaceuticals, Inc. is appointing Rami Levin as its new Chief Executive Officer and President effective January 1, 2026, following the resignation of John Climaco on December 16, 2025. Levin will also join the Board of Directors on January 1, 2026.
Levin’s employment agreement sets an initial annual base salary of $580,000, a target annual bonus equal to 50% of base salary based on goals set by the Compensation Committee, and eligibility for annual equity grants. He will receive an initial grant of 19,000 restricted stock units, vesting 25% after six months, 25% after twelve months, and the remaining 50% in twelve quarterly installments, subject to continued employment. If terminated without cause or if he resigns for good reason, he is entitled to 12 months of base salary, a target bonus for the post-year-end period, and accelerated vesting of all unvested equity, subject to a release and covenants.
Under a separation agreement, Climaco will receive 12 months of his current annualized base salary in monthly installments, salary through December 31, 2025, his 2025 cash bonus of $319,000 paid over 12 months, and 12 months of employer-paid COBRA premiums, conditioned on his execution and compliance with the agreement.
CNS Pharmaceuticals, Inc. reported results of its 2025 annual stockholder meeting and related corporate changes. Stockholders approved an amendment to the company’s Amended and Restated Articles of Incorporation to increase authorized common stock from 25,000,000 shares to 300,000,000 shares and authorized preferred stock from 416,667 shares to 5,000,000 shares, and the company filed the amendment in Nevada to make these changes effective. They also approved amendments to the 2020 Equity Plan, raising the number of shares of common stock that may be issued under the plan to 115,061 shares.
All director nominees were elected to serve until the 2026 annual meeting, the appointment of MaloneBailey, LLP as independent auditor for the year ending December 31, 2025 was ratified, and executive compensation was approved on an advisory basis. Stockholders recommended holding the advisory say‑on‑pay vote every year, and the board chose an annual frequency in line with that recommendation. As of the October 10, 2025 record date, 574,580 shares of common stock were issued and outstanding, with 204,107 shares represented at the meeting, constituting a quorum.
CNS Pharmaceuticals, Inc. (CNSP) reported a Form 4 showing a director received an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share. The option was originally approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan, which shareholders granted on November 17, 2025. The option becomes exercisable in four equal quarterly installments starting on the November 17, 2025 shareholder approval date, as long as the director continues in employment on each vesting date, and expires on November 17, 2035. The filing states the option was issued in connection with the reporting person’s employment and is held as a direct ownership position.
CNS Pharmaceuticals, Inc. (CNSP) reported a Form 4 filing for a director covering a new stock option grant. The derivative security is an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, expiring on November 17, 2035.
The grant was approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan. Shareholders approved the plan at the annual meeting on November 17, 2025, defined as the “Shareholder Approval Date.” The options vest in four equal quarterly installments starting on the Shareholder Approval Date, contingent on the reporting person’s continued employment. After this transaction, the reporting person beneficially owns 1,517 derivative securities directly.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to its chief executive officer and director on a Form 4. The filing shows an option to purchase 9,761 shares of common stock at an exercise price of $30 per share, dated 11/17/2025 and expiring on 11/17/2035.
The option was originally approved on 03/11/2025, subject to shareholder approval of the stock option plan, which was obtained on 11/17/2025. The grant vests over 18 months: 50% on the six‑month anniversary of the grant date, 25% on the 12‑month anniversary, and 25% on the 18‑month anniversary, conditioned on continued employment. The reporting person beneficially owns 9,761 derivative securities directly after this transaction.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant on a Form 4 for a director. The filing shows an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, approved by the compensation committee on June 6, 2025 and made effective upon shareholder approval on November 17, 2025. The option vests in four equal quarterly installments beginning on the shareholder approval date, contingent on continued employment at each vesting date, and carries an expiration date of November 17, 2035. The option was issued in connection with the reporting person’s employment with the company.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to a director on a Form 4. The filing shows an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, dated 11/17/2025 with an expiration date of 11/17/2035.
The grant was originally approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan. Shareholders approved the plan at the annual meeting on November 17, 2025, which is also the “Shareholder Approval Date.” The options vest in four equal quarterly installments starting on that approval date, conditioned on the director’s continued service with the company.
CNS Pharmaceuticals, Inc. reported an equity compensation grant to its Chief Financial Officer, Christopher Downs, on a Form 4. The filing shows an option to purchase 4,881 shares of common stock at a conversion or exercise price of
CNS Pharmaceuticals’ shareholders approved the plan at the annual meeting on
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to one of its directors on Form 4. On November 17, 2025, the director received an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, with an expiration date of November 17, 2035.
The option was originally approved by the compensation committee on June 6, 2025, and became effective after shareholders approved the underlying stock option plan on November 17, 2025, described as the Shareholder Approval Date. The options vest in four equal quarterly installments starting on that approval date, conditioned on the director’s continued employment with the company. The filing notes that the option was issued in connection with the reporting person’s employment and is held as a direct ownership position.
CNS Pharmaceuticals reported Q3 2025 results with a narrower net loss of
For the nine months, net loss improved to
FAQ
What is the current stock price of CNS Pharmaceuticals (CNSP)?
What is the market cap of CNS Pharmaceuticals (CNSP)?
